2026-04-29T04:10:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/170542024-11-28T15:08:01Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Avigan, Mark I author Bjornsson, Einar S author Pasanen, Markku author Cooper, Charles author Andrade, Raul J author Watkins, Paul B author Lewis, James H author Merz, Michael author 2014-01 A workshop was convened to discuss best practices for the assessment of drug-induced liver injury (DILI) in clinical trials. In a breakout session, workshop attendees discussed necessary data elements and standards for the accurate measurement of DILI risk associated with new therapeutic agents in clinical trials. There was agreement that in order to achieve this goal the systematic acquisition of protocol-specified clinical measures and lab specimens from all study subjects is crucial. In addition, standard DILI terms that address the diverse clinical and pathologic signatures of DILI were considered essential. There was a strong consensus that clinical and lab analyses necessary for the evaluation of cases of acute liver injury should be consistent with the US Food and Drug Administration (FDA) guidance on pre-marketing risk assessment of DILI in clinical trials issued in 2009. A recommendation that liver injury case review and management be guided by clinicians with hepatologic expertise was made. Of note, there was agreement that emerging DILI signals should prompt the systematic collection of candidate pharmacogenomic, proteomic and/or metabonomic biomarkers from all study subjects. The use of emerging standardized clinical terminology, CRFs and graphic tools for data review to enable harmonization across clinical trials was strongly encouraged. Many of the recommendations made in the breakout session are in alignment with those made in the other parallel sessions on methodology to assess clinical liver safety data, causality assessment for suspected DILI, and liver safety assessment in special populations (hepatitis B, C, and oncology trials). Nonetheless, a few outstanding issues remain for future consideration. http://hdl.handle.net/10668/1881 http://hdl.handle.net/20.500.12105/17054 25352325 10.1007/s40264-014-0183-6 0114-5916 Drug Safety Enfermedad hepática Inducida por Drogas Farmacogenética Estándares de referencia Medición de riesgo Pruebas diagnósticas de rutina Ensayos clínicos como asunto Proteómica Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.